HC Wainwright & Co. Maintains Buy on Actinium Pharma, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Actinium Pharma (ATNM) with a maintained price target of $50.
March 11, 2024 | 2:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Actinium Pharma maintains a Buy rating and a $50 price target from HC Wainwright & Co., indicating a positive outlook on the stock.
The maintenance of a Buy rating and a $50 price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong confidence in Actinium Pharma's future performance. This endorsement is likely to instill investor confidence and could lead to a positive short-term impact on ATNM's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100